cyrilzakka/clinical-trials huggingface dataset:
Quinolone Resistance in Bloodstream Isolates of Escherichia Coli

This proposed study aims to document the risk factors for quinolone resistance in bloodstream isolates of E. coli. Additionally, the adequacy of empiric antibiotic therapy for E. coli bloodstream infections will be assessed. Finally, outcome will be recorded - this is all-cause mortality at 28 days from the time of the first positive blood culture. Hypothesis: Ciprofloxacin resistant strains are associated with admission from nursing home and with prior quinolone use.

The following information will be collected: age, sex, occupation, hospital location at the time of positive culture (ER, medical ward, ICU etc), date of positive culture, prior hospitalization, receipt of outpatient dialysis, home care or other regular medical care (eg, outpatient chemotherapy), presence of invasive devices, receipt of antibiotics, including their type and whether they were adequate for the resistance profile of the organism, prior positive microbiologic cultures, time and location of positive cultures, underlying diseases and severity of illness, presence of urinary or intravascular devices, recent immunomodulative therapies or radiation therapy, physical exam findings, laboratory and radiographical data, antimicrobial usage within 30 days of onset of the infection, microbiological data and resistance patterns, choice of antibiotics once organism identified, bacteriological outcomes, laboratory results, demographic information, medications, clinical outcome,gender, height, weight, ethnicity, and past medical history. We will collect information retrospectively.

Eligibility Criteria:
Inclusion Criteria:

Clinical information is collected by chart review of "case" and "control" patients.

A "case A" patient is defined as follows:

* One or more blood cultures are positive for E. coli. The organism is ciprofloxacin resistant.

A "case B" patient is defined as follows:

* One or more blood cultures are positive for E. coli. The organism is ciprofloxacin susceptible. Additionally, 4 controls who are in hospital at the same time as cases will be selected for each case.

Exclusion Criteria:

* If they do not meet inclusion criteria
Metabolic Heterogeneity Underlying Hypertriglyceridemia: Hepatic Triglyceride Biosynthesis in Humans with Different Insulin Resistance Phenotypes

The focus of this cross-sectional study is to determine the effects of tissue-specific (adipose tissue or muscle) vs global (combined) insulin resistance (IR) on hepatic triglyceride biosynthesis in humans, and to determine differential effects of an acute exercise intervention on hepatic triglyceride biosynthesis in these groups.

Hypothesis: Patients who primarily have muscle IR will have a greater percentage of lipids derived from de novo lipogenesis (DNL) than patients with combined muscle and adipose IR, and these subjects will respond more robustly to the effects of premeal exercise.

With this study, the investigators will demonstrate that the mechanisms that drive triglyceride overproduction in insulin-resistant humans are dependent on which tissues are insulin resistant. To this end, investigators will determine whether subjects with muscle insulin resistance and adipose tissue insulin resistance utilize different mechanisms of triglyceride biosynthesis to assemble hepatic very low density lipoprotein (VLDL), as compared with individuals with muscle insulin resistance but relative adipose tissue insulin sensitivity. Additionally, investigators will see if adipose tissue insulin sensitivity predicts exercise responsiveness of hepatic triglyceride production.

Main study parameters/endpoints: Difference in %DNL between subjects with global vs muscle-only insulin resistance as well as the differential effects of premeal exercise on %DNL in these groups.

Eligibility Criteria:
Inclusion Criteria:

* Ability to give informed consent
* Overweight, defined as BMI 25-30 kg/m2
* Modest hypertriglyceridemia, defined as fasting plasma triglycerides 1.5-3.0mM
* High risk of insulin resistance, defined as fasting plasma insulin \>64pM
* Stable weight for at least 3mo prior to participation

Exclusion Criteria:

* Active or chronic liver disease, kidney disease, congestive heart failure, unstable angina, history of acute cardiovascular events within 6mo of screening, history of seizures or syncope, or an active infection requiring antimicrobial therapy;
* Use of insulin, thiazolidinediones, SGLT2 inhibitors, or sulfonylureas;
* Use of fibrates, omega 3 (fish oil), niacin, or PCSK9 antagonists;
* Use of systemic glucocorticoids within 60d prior to participation;
* Hematocrit \<35%;
* Pregnancy of breastfeeding;
* Active tobacco use, excessive alcohol intake (\>14U/wk), or history of drug abuse.
Artificial Intelligence (AI) Validation Study for Polyp Detection

Interventional prospective multicenter study: Polyp detection by an automated endoscopic tool as second observer during routine diagnostic colonoscopy

This is an investigator-initiated multicentre non-randomized prospective interventional trial to validate the performance of a novel state-of-the-art computer-aided diagnostic (CAD) tool in polyp detection implemented as second observer during routine diagnostic colonoscopy and to evaluate its feasibility in daily endoscopy. Patients referred for a screening surveillance or therapeutic colonoscopy will undergo a colonoscopy performed by an endoscopist with moderate to high adenoma detection rate (ADR \> 20% and \< 50%) while a second observer will follow the procedure on a bedside AI-tool to count the number of detections made by the AI system and categorize the results into positive or negative results as follows (1) true positive, (2) false negative, (3) other positive and (4) obvious false positive. When a doubtful detection is made by the AI-system, the second observer will ask to re-evaluate the indicated region. When the detection is clear, the endoscopist and second observer do not communicate. The entire procedure is recorded.

Eligibility Criteria:
Inclusion Criteria:

* \> 18 years
* Diagnostic or screening colonoscopy
* Therapeutic colonoscopy

Exclusion Criteria:

* Inability to give informed consent by the patient or legal representative
* \< 18 years old
* Any contraindication for colonoscopy or biopsies of the colon
* Uncontrolled coagulopathy
* Confirmed diagnosis of inflammatory bowel disease
* Short bowel or ileostomy
* Pregnancy
The Role of the Coagulation Pathways in Recurrent Angioedema

Previous studies reported infraclinical modifications of the homeostasis in chronic urticaria, recurrent idiopathic angioedema and hereditary angioedema. This study aim to compare groups with isolated wheals, isolated angioedema, combination of both and hereditary angioedema in terms of coagulation pathways.

Previous studies reported infraclinical modifications of the homeostasis in chronic urticaria, recurrent idiopathic angioedema and hereditary angioedema. This study aim to compare groups with isolated wheals, isolated angioedema, combination of both and hereditary angioedema in terms of coagulation pathways. the main objective is to highlight a difference between the rates of different coagulation factors in the 3 groups presenting different categories of angiodemes patients with a group of patients with isolated superficial chronic urticaria

Eligibility Criteria:
Inclusion Criteria:

* recurrent angioderma

Exclusion Criteria:

* anticoagulant therapy, diseases of hemostasis
PPIs and In-Hospital Morbidity in Acute Variceal Bleeding with Chronic Liver Disease

With this study, the investigators pretend to describe intrahospital morbidity in patients living with cirrhosis (PLC) who present to the emergency department with variceal bleeding (VB).

This study is a longitudinal, prospective, experimental, analytical single-center clinical trial. The study will be performed in the Hospital Universitario "Jose E. González" de la Factultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, México.

The studied population consists of adult-age patients with previous, recent, or new diagnoses of cirrhosis who present to the ED with VH without shock, infection, or acute or chronic disease with a \<30% probability of death (CLIF-C \<50). The exclusion criteria involve minor age, Acute Liver Failure (ALF), ICU patients, Hepatorenal Syndrome, sepsis or infection, and shock on admission except for hypovolemic and CLIF-C \>50 points. Elimination criteria involve patients who want to discontinue treatment and patients with confounding endoscopic findings (Erosive esophagitis, peptic ulcers, duodenal ulcers, GAVE, and atrophic gastritis).

After the endoscopic intervention, the investigators will propose inclusion. After acceptance with Informed Consent, the investigators will randomize the patients to receive or not receive Omeprazole 40 mg IV per day until discharge. The primary outcome will represent several morbidity situations in these patients, including Hepatic Encephalopathy, intra-hospital infections, re-bleeding, shock, and acute kidney failure.

The secondary outcomes include the individual analysis of each component of our compound primary outcome, mortality by day 30, differences when grouping patients by Child-Pugh stratification, and comparing results in patients receiving omeprazole for more or less than 5 days.


Eligibility Criteria:
Inclusion Criteria

* Adult
* Cirrhosis
* Variceal Bleeding with only endoscopic findings consistent with portal hypertension complications
* Hypovolemic shock and Variceal bleeding

Exclusion Criteria:

* Shock of any type other than hypovolemic.
* No cirrhotic patients
* Patients that have Hepatic Encephalopathy at admission
* Hepatorenal syndrome
* Acute on chronic with CLIF-C \>50 points
* Septic patients
* Spontaneous Bacterial Peritonitis

Elimination Criteria

* Voluntary removal of the study
* Patients with confounding endoscopic findings (Erosive esophagitis, peptic ulcers, duodenal ulcers, GAVE, and atrophic gastritis).
A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular Degeneration

The objectives of this study are to evaluate the safety, tolerability, and pharmacokinetic profile of volociximab intravitreous injection in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD).


Eligibility Criteria:
Inclusion Criteria:

* Subfoveal choroidal neovascularization (CNV) due to AMD (i.e., predominantly classic, minimally classic or occult no classic) as documented by fluorescein angiogram.

Exclusion Criteria:

* Any prior treatment for AMD or any intravitreal treatment for any indication in the study eye prior to the screening visit, except oral supplements of vitamins and minerals.
* Previous or concomitant therapy with intravitreous corticosteroids.
* Any of the following underlying diseases including:
* Diabetic retinopathy
* History or evidence of severe cardiac disease (e.g., NYHA Functional Class III or IV - see Appendix 19.6), history or clinical evidence of unstable angina, acute coronary syndrome, myocardial infarction or revascularization within last 6 months, ventricular tachyarrythmias requiring ongoing treatment.
* History or evidence of clinically significant peripheral vascular disease, such as intermittent claudication or prior amputation.
* Clinically significant impaired renal (serum creatinine \>2.5 mg/dl or s/p renal transplant or receiving dialysis) or hepatic function. Patients with results outside these ranges may be enrolled in consultation with Ophthotech.
* Stroke (within 12 months of trial entry).
* Any major surgical procedure within one month of trial entry.
* Previous therapeutic radiation in the region of the study eye.
* Any treatment with an investigational agent in the past 60 days for any condition.
* Women who are pregnant or nursing.
* Known serious allergies to the fluorescein dye used in angiography, to the components of the ranibizumab formulation, or to the components of the volociximab formulation.
Vitamin D Status in Pediatric Asthma

The purpose of this study is to evaluate level of vitamin D in pediatric asthma and relationship between vitamin D and level control of asthma.

cross-sectional study

Eligibility Criteria:
Inclusion Criteria:

* children between the age of 6 years and 18 years with the diagnosis of asthma who are attending the outpatient pediatric department, pediatric allergy clinic

Exclusion Criteria:

* patients who have chronic pulmonary, heart disease, chronic renal failure, liver disease, endrocrine disorder, or receieve antiepileptic drugs, vitamin D supplement
Research on the Effect and Mechanism of Aerobic Exercise on PD

This trial is expected to recruit patients with primary Parkinson's disease and give them four consecutive weeks of aerobic exercise to observe its effect on Parkinson's disease and explore its mechanism

This trial is expected to recruit patients with primary Parkinson's disease who are distributed into tremor group and stiff group and give them the same kind of four consecutive weeks of aerobic exercise to observe its effect on Parkinson's disease and explore its mechanism

Eligibility Criteria:
Inclusion Criteria:

* Participants were diagnosed primary PD according to the 2015 MDS diagnostic criteria
* Participants are between 55 and 65 years old

Exclusion Criteria:

* Severe heart
* liver dysfunction
* kidney dysfunction
* severe cognitive dysfunction
* severe anxiety and depression
* history of mental illness
* history of cerebral infarction or ischemic attack in the past three months
* acute myocardial infarction or acute coronary in the past three months
* Parkinson's Pulse syndrome
* medication history (drugs that improve blood circulation in the brain and increase the excitability of the nervous system)
Patient Education and Text Message Reminders in Colonoscopy

This study will be conducted to examine the effects of detailed education and text message reminders given to patients undergoing colonoscopy on bowel cleansing, vital signs and anxiety.

İntroduction: The highest level of bowel preparation before the colonoscopy procedure is necessary for the successful completion of colonoscopy. Considering that the bowel preparation procedures required for colonoscopy are performed by patients, it is very important to inform patients about the content and duration of diet and bowel preparation practices. Today, with the widespread use of technology in our lives, technological education methods such as web-based trainings, text message reminders, telemedicine methods have started to be used in patient education methods as well as classical methods.

Purpose: This study will be conducted to examine the effects of detailed education and text message reminders given to patients undergoing colonoscopy on bowel cleansing, vital signs and anxiety.

Method: This study will be a randomized controlled trial. hospital. The sample of the study will include individuals who will undergo colonoscopy procedure in the endoscopy unit of a state hospital and who meet the inclusion criteria. Data will be collected using personal information form, beck anxiety scale, boston bowel readiness scale. In this study, in addition to the standard patient education protocol, the effectiveness of colonoscopy education with more intensive content and supported by visuals and diagrams will be evaluated in the education group. Individuals in the other group will receive text message reminders, which is one of the new methods that have started to be used in patient education with the technology that has become widespread today.

Conclusion: It is thought that more intensive and materialized trainings and text message reminders to patients compared to standard colonoscopy preparations will increase the level of bowel cleansing, improve vital signs and reduce anxiety.

Eligibility Criteria:
Inclusion Criteria:

Individuals who understand Turkish

Individuals who know how to use a phone and read text messages

Individuals over 18 years of age

Patients undergoing colonoscopy for the first time

Exclusion Criteria:

Patients with cognitive dysfunction

Patients with neuro-psychiatric disorders

Individuals who do not know how to use a phone

Individuals undergoing colonoscopy in emergency situations

Individuals who did not give consent to participate in the research
Impact of Capsular Tension Ring Implantation on Intraocular Lens Position

This is a randomized controlled trial to investigate the effect of capsular tension ring (CTR) implantation on intraocular lens (IOL) tilt and decentration in cataract patients with high myopia.

Exact positioning and alignment of the IOL with the visual axis are the prerequisites of high-quality visual performance after cataract surgery. A certain degree of IOL tilt and decentration occur after uneventful cataract surgery, most of which are clinically tolerant. However, the relatively large capsular bag volume, zonular weakness, and vitreous liquefaction in cataract patients with high myopia may increase the IOL position instability, such as tilt, decentration and even dislocation, leading to the deterioration of visual function. Thus, how to improve the long-term stability of IOL position in high myopic cataract patients is an urgent issue to be addressed.

Previous studies have shown that CTR implantation during cataract surgery can increase the IOL stability in patients with normal axial length; however, its impact on IOL position of cataract patients with high myopia remains unclear.

In this randomized clinical trial, patients who meet the inclusion criteria will be divided into three layers according to the axial length:

(1)26mm≤AL\<28mm (2)28mm≤AL\<30mm (3)AL≥30mm

We are going to recruit 186 patients in total, with 62 patients in each layer. Patients on each layer will be randomly divided into experimental group (CTR implantation) and control group (only IOL implantation). If both eyes of a patient meet the inclusion criteria, only the first operated eye is included in the statistics analysis.

All included patients will be followed up at 1 week, 1 month, 3 months, 6 months, and 1 year postoperatively. Visual acuity, IOL tilt, IOL decentration, posterior capsule attachment with IOL, anterior capsule contraction, posterior capsular opacification, and visual quality will be measured and compared between the experimental group and the control group at different timepoints.

Eligibility Criteria:
Inclusion Criteria:

1. \> 18 years old;
2. axis length≥26mm;
3. Visually significant cataract;
4. The patient is willing and able to complete all necessary follow-ups and examinations.

Exclusion Criteria:

1. Intraoperative or postoperative complications: such as intraoperative posterior capsular rupture, zonular dehiscence, secondary glaucoma, endophthalmitis, etc.;
2. Other ocular comorbidity: such as keratopathy, glaucoma, uveitis, retinopathy, lens dislocation and ocular trauma, etc.;
3. History of intraocular surgery;
4. Severe systemic diseases: such as severe hypertension, diabetes, heart disease, Alzheimer's, Parkinson, etc.;
5. Any condition that the study physician considers to be an impediment to the clinical trial.
Clinical Effects of Temperature Controlled Laminar Airflow (TLA)

The purpose of this study is to determine whether clean air administered to the breathing zone with Temperature controlled Laminar Airflow (TLA) during night is effective in the treatment of perennial allergic asthma.

Background: Exposure to inhaled allergens is a pathogenetic factor in allergic asthma. However, most studies that previously looked at air cleaning devices have shown little or no effect on patients with perennial allergic asthma. Aims and objectives: This study aims to investigate a novel treatment, TLA, using temperature controlled laminar airflow with a very low particle concentration directed to the breathing zone of teenagers and adults with allergic asthma during night sleep. The hypothesis is that the decreased allergen exposure during the night will have an effect on bronchial inflammation and quality of life. Method: Patients are randomized to start with active or placebo treatment for 10 weeks. All patients receive both active and placebo treatment with unfiltered air, with a 2-week wash-out period in between treatments. Maintenance treatment with inhaled corticosteroids is unaltered during the trial period. Health related quality of life (miniAQLQ)is the primary effectiveness measure. Exhaled nitric oxide (FeNO) and spirometry are also investigated.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosed for asthma for more than 1 year.
* More than 12% reactivity in FEV1 on bronchodilating medication or less than 90% of the FEV1 reference value according to Hedenström.
* Perennial allergy
* At least 3-mm wheal reaction in a skin prick test to at least one of following: House dust, Mold spores, dust mites, animal hair and dander.
* Little or no reactivity to other inhalant allergens.
* No known allergy to another inhalant allergen or chemical to which there is exposure in winter time.
* No allergen injection treatment in the preceding 2 years.
* A history of a requirement for daily medication for asthma including;

  * 400µg steroid medication (Pulmicort or equal) for children and 800µg for adults.
  * Beta agonist treatment on less than 4 days per week.
* Willingness to follow the clinical trial protocol, including medications, baseline and follow-up visits and procedures.

Exclusion Criteria:

* Inclusion in another Allergen avoidance program.
* Smoking in the family
* Participation in a drug trial
The Effect of Vitamin D and Exercise on Balance in Postmenopausal Women

In recent years, skeletal and nonskeletal effects of vitamin D has been studied. One of the effects of it was balance and fall prevention. However, these studies were performed on older patients who had not vitamin D deficiency. This study aimed to evaluate the effect of vitamin D replacement therapy and exercise on balance in 50-70 years-old postmenopausal women.


Eligibility Criteria:
Inclusion Criteria:

* 50-70 years-old postmenopausal women
* Vitamin D level\<10 ng/ml and Vitamin D level\>30 ng/ml
* Independant in daily life
* Able to do exercise
* Able to read and write in Turkish

Exclusion Criteria:

* Diabetes mellitus,
* Polyneuropathy,
* Spinal stenosis,
* History of fracture or lower extremity operation,
* Rheumatologic diseases,
* History of chemotherapy
* Cognitive impairment